Revenue from major products of Fosun Pharmaceutical 2022, by therapeutic area
In 2022, the Chinese pharmaceutical firm Fosun Pharmaceutical generated around 44 billion yuan of revenue, representing a growth of 12.7 percent from the previous year. Although anti-infection products remained the company's most important source of income, anti-tumor and immune modulation medications, such as trastuzumab and adalimumab, contributed more than 5.5 billion yuan of Fosun's revenue in 2022, almost 40 percent more than in 2021.